We are live on ! Find out more
PASG icon

Passage Bio

102 hedge funds and large institutions have $557M invested in Passage Bio in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 17

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

15% more funds holding

Funds holding: 89102 (+13)

0.05% less ownership

Funds ownership: 4.18%4.13% (-0.05%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

29% less capital invested

Capital invested by funds: $786M → $557M (-$229M)

99% less call options, than puts

Call options by funds: $3K | Put options by funds: $246K

Holders
102
Holders Change
+13
Holders Change %
+14.61%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
22
Increased
42
Reduced
17
Closed
9
Calls
$3K
Puts
$246K
Net Calls
-$243K
Net Calls Change
-$243K

PASG Hedge Fund Activity: Q2 2021 in Review

102 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2021, worth a combined $557M — down 29% from $786M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PASG positions and 9 closed out — a net gain of 13 holders — while 42 added to existing stakes and 17 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $8.36M. The largest seller was Fidelity Investments, cutting an estimated $23.4M.

  • 102 institutional investors held Passage Bio (PASG) as of Q2 2021, up from 89 in Q1 2021.
  • Funds reported $557M of Passage Bio stock for Q2 2021, down 29% quarter-over-quarter.
  • 22 funds opened new Passage Bio positions in Q2 2021 and 9 closed out, a net change of +13 holders.
  • The largest Passage Bio buyer in Q2 2021 was Morgan Stanley, an estimated $8.36M added.
  • The largest Passage Bio seller in Q2 2021 was Fidelity Investments, an estimated $23.4M sold.

Based on aggregated 13F filings for Q2 2021.